Jim Cramer Finds Pfizer (PFE)’s Stock Level “Unfathomable”

Core Insights - Pfizer Inc. (NYSE:PFE) is perceived to trade more like a bond due to its 7% dividend yield, which has raised concerns about its stock performance despite a solid balance sheet and promising pipeline [2][3] - CEO Albert Bourla acknowledged the stock's undervaluation and addressed concerns regarding high tariffs, reliance on COVID revenue, and the company's strategy in the weight loss drug market [2] - The loss of exclusivity for Pfizer's drugs is a significant concern, and the company is actively working to mitigate this issue [2] Stock Performance - Jim Cramer expressed disbelief that Pfizer's stock remains at a 7% yield despite a strong quarterly performance and a robust balance sheet [3] - Cramer highlighted the disconnect between the company's performance and its stock price, indicating that the current valuation is "unfathomable" [3]